ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

ClinicalTrials.gov ID: NCT06862791

Public ClinicalTrials.gov record NCT06862791. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 10:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Co-administration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight With Co-morbidity (ASCEND)

Study identification

NCT ID
NCT06862791
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
AstraZeneca
Industry
Enrollment
377 participants

Conditions and interventions

Interventions

  • AZD6234 Drug
  • AZD9550 Drug
  • Placebo comparator Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 17, 2025
Primary completion
May 24, 2026
Completion
May 24, 2026
Last update posted
Apr 27, 2026

2025 – 2026

United States locations

U.S. sites
29
U.S. states
20
U.S. cities
29
Facility City State ZIP Site status
Research Site Dothan Alabama 36305
Research Site Vestavia Hills Alabama 35216
Research Site Cerritos California 90703
Research Site Escondido California 92025
Research Site Huntington Park California 90255
Research Site Lincoln California 95648
Research Site Sacramento California 95864
Research Site Waterbury Connecticut 06708
Research Site Palm Harbor Florida 34684
Research Site Decatur Georgia 30030
Research Site Stockbridge Georgia 30281
Research Site Champaign Illinois 61822
Research Site South Bend Indiana 46617
Research Site Valparaiso Indiana 46383
Research Site Sioux City Iowa 51106
Research Site Southfield Michigan 48034
Research Site Missoula Montana 59804
Research Site Omaha Nebraska 68114
Research Site Albuquerque New Mexico 87107
Research Site Fargo North Dakota 58104
Research Site Cincinnati Ohio 45219
Research Site Columbus Ohio 43213
Research Site Tulsa Oklahoma 74133
Research Site Medford Oregon 97504
Research Site Kingsport Tennessee 37660
Research Site Brownsville Texas 78526
Research Site Houston Texas 77043
Research Site Arlington Virginia 22206
Research Site Renton Washington 98057

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06862791, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 27, 2026 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06862791 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →